Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of INM004 for pediatric STEC-associated hemolytic uremic syndrome
2024-512412-22-00Phase 3Authorised
- Sponsor
- Chemo
- Start
- Jun 2025
- Modality
- Fab Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial in hemolytic uremic syndrome (HUS) and Shiga toxin-producing Escherichia coli infection (STEC) comparing INM004 with Placebo (2 arms). Primary endpoint: Time to recovery of renal function during the acute phase. Planned start Jun 2025; status: authorised.
02
Drugs
equine immunoglobulin F(ab')2 fragments targeting Shiga toxin
03
Conditions
hemolytic uremic syndrome (HUS)Shiga toxin-producing Escherichia coli infection (STEC)
Beyond the preview
Go deeper on 2024-512412-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512412-22-00.